Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Tnp3.8
Tianeptine – Forschung
Überwiegend Mechanismus / Beobachtung
15 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Tianeptine sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2002–2026 mit einer typischen Studiengröße von 1,055 Teilnehmenden.
Basierend auf 15 Studien · 2 Meta-Analysen · 2 RCTs · 1,080 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Safety profile
Überwiegend Mechanismus / Beobachtung13 Studien
Antidepressant effectBei der verordneten Dosis (12,5 mg dreimal täglich) hat Tianeptin die kurzfristige antidepressive Wirksamkeit reproduziert — in einer Meta-Analyse von fünf RCTs mindestens so wirksam wie SSRIs · 1-6 Wochen bei therapeutischer Dosis
Überwiegend Mechanismus / Beobachtung10 Studien
Anxiety & anxious depressionZeigt bei der therapeutischen Dosis im überwachten klinischen Einsatz neben seiner antidepressiven Wirkung auch anxiolytische Effekte · Wochen bei therapeutischer Dosis
Zu wenige bewertete Studien2 Studien
Glutamatergic plasticity & stress remodelling
Zu wenige bewertete Studien2 Studien
Aktives Forschungsgebiet
9 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200220142026
1Systematische Übersicht2026
It also highlights the importance of comprehensive inquiry into substance exposure and discussion regarding minimizing the risks of exposure in the setting of limited perinatal data.
Jones CW, Manriquez M, Chavan NR. · Obstetrics and gynecology (2026)
New exposures to substances include adulterants found in established drug supplies such as fentanyl, xylazine, nitazenes, and medetomidine, and substances promoted as herbal or natural supplements such as kratom and tianeptine.
In addition, there are prescription medications being used in new or unintended ways, such as ketamine.
This narrative review details some of the most common substances currently emerging in the United States and discusses the potential effects on pregnancy outcomes.
Continued clinical and epidemiological observation is warranted.
Anand A, Alessi MR, Toussi RA, Tian J, Raffoul JJ, Pratt N, Nero N, Weleff J. · Drug and alcohol dependence (2026)
Among individual cases (n = 52), 26/52 (50%) presented with withdrawal and 23/52 (44%) with overdose.
Long-term treatment for withdrawal included buprenorphine 5/26 (19%) and methadone 1/26 (4%).
Overdose presentations commonly involved central nervous system depression, respiratory failure, and rhabdomyolysis; among overdose cases with detailed data (n = 22), naloxone was administered in 6/22 (27%), and fatalities occurred in 7/22 (32%).
Clinical relevance This study informs health professionals that certain antidepressants may positively impact the periodontium, while also highlighting the need for further research evaluating their possible influence on the human periodontal condition and their potentially associated local/systemic adverse effects.
There was no standardization of the duration of use, type, and dosage of medication between studies.
Conclusions Animal studies suggest antidepressants modulate the immunoinflammatory response and prevent alveolar bone loss in experimental periodontitis, but their impact on human periodontal status remains controversial.
Standardized methods are needed to clarify antidepressant effects on the periodontium.
This systematic-review examined the effects of Tianeptine.
Norred MA, Zuschlag ZD, Hamner MB. · Drugs (2024)
Presently, only two medications are US FDA-approved for the treatment of PTSD, both selective serotonin reuptake inhibitors (SSRIs).
However, the complex underlying pathophysiology suggests a number of alternative pathways and mechanisms that may be targets for potential drug development.
Indeed, investigations and drug development are proceeding in a number of these alternative, non-serotonergic pathways in an effort to improve the management of PTSD.
It is the aim of this review to discuss the medicinal chemistry and pharmacology of tianeptine and to summarize this intriguing discrepancy between tianeptine's historical use as a safe and effective antidepressant and its emerging potential for abuse.
Nishio Y, Lindsley CW, Bender AM. · ACS chemical neuroscience (2024)
Additionally, tianeptine's efficacy may be related to its action on glutamate-mediated pathways of neuroplasticity.
Regardless of which neurotransmitter system is primarily responsible for the observed efficacy, the MOR agonist activity is problematic with respect to abuse liability.
Increasing numbers of case reports have demonstrated that tianeptine is indeed being used recreationally at doses far beyond what are considered therapeutically relevant or safe, and scheduling reclassifications or outright bans on tianeptine products are ongoing around the world.
Further clinical trials are needed to confirm these results.
Taccardi D, Chiesa A, Maiorani C, Pardo A, Lombardo G, Scribante A, Sabatini S, Butera A. · Journal of clinical medicine (2024)
Most trials showed improvements in periodontal health, especially with fluoxetine, but also with imipramine, desipramine, desvenlafaxine and tianeptine; on the contrary, worsening of clinical periodontal indices and increased loss of alveolar bone were reported with venlafaxine.
Healthcare professionals (especially oral and mental health professionals) should investigate proper adherence to medication therapy in patients with a history of periodontitis and depression.
Further clinical trials are needed to confirm these results.
Park HY, Park J, Roh D, Jhung K, Chang JG, Park S, Ryu JS, Do G, Lee K, Park JY, Kim WJ. · Brain and behavior (2025)
Results Both groups showed significant improvements in depressive symptoms and cognitive performance across four assessment points (baseline, Weeks 3, 6, and 12).
Linear mixed-effects models revealed a significant main effect of time for both BDI (F = 33.67, p < 0.001) and MADRS scores (F = 34.50, p < 0.001), with no significant group-by-time interaction, indicating comparable efficacy between protocols.
Model-derived mean changes from baseline to Week 12 were -7.53 (95% CI -9.85 to -5.21) for BDI and -6.61 (95% CI -8.73 to -4.49) for MADRS.
Targeted prevention, regulation, and treatment interventions are urgently needed to address these challenges.
Parnia S, Jain L, Ali M, Sarfraz Z, Nasir MJ, Shah D, Fnu A, Atiq N, Shaikh PR, Ahmed R, Hower M, Karlapati S, Moazzam MT, Bazin B, Ahmed S. · BMC public health (2025)
Results Tianeptine misuse demonstrated notable regional variations, with North America accounting for 40/52 (76.92%) of cases, followed by Asia 8/52 (15.38%) and Europe 4/52 (7.69%) (X²=44.9231, p < 0.0001).
The majority of users were male 29/52 (55.77%) (X²=0.6923, p = 0.4054), and oral ingestion was the predominant route 37/52 (71.15%), while intravenous use accounted for 5/52 (9.62%) (X²=88.3846, p < 0.0001).
Habitual misuse was documented in 30/52 (57.69%) of cases (X²=1.2308, p = 0.2673).
In this review, we discuss the strengths, problems, and limitations of the studies, as well as areas in need of further investigation.
Fricker LD, Osman A, Gupta A, Gomes I, Devi LA. · Biochemical pharmacology (2025)
Chronic antidepressant treatment of mice causes changes in gene expression.
Interestingly, proenkephalin is one of the most highly upregulated genes following long-term treatment of mice with fluoxetine, a selective serotonin reuptake inhibitor.
Taken together, these findings suggest that the opioid system plays an important role in major depressive disorder.
None of the assessed parameters (MADRS total score and responder rate) revealed any significant difference between the two treatment groups ... tianeptine is at least as effective as SSRI, with a trend for a better acceptability profile in the treatment of depressed patients.
Kasper S, Olié JP. · European Psychiatry (2002)
Meta-analysis of five randomized controlled trials (1,348 patients: 667 tianeptine, 681 SSRI) comparing short-term antidepressant efficacy of tianeptine versus fluoxetine, paroxetine and sertraline
No significant difference between tianeptine and SSRIs on MADRS total score or responder rate — tianeptine at least as effective as SSRIs
A trend favoured tianeptine on the CGI therapeutic-index item (better acceptability), supporting comparable efficacy with possibly better tolerability at the therapeutic dose
Tianeptine appears to be as effective and as safe as paroxetine for the ambulatory treatment of major depression.
Waintraub L, Septien L, Azoulay P. · CNS Drugs (2002)
3-month randomized, double-blind trial in 277 outpatients with major depression: tianeptine 12.5 mg three times daily versus paroxetine 20 mg/day across 82 French centres
Both groups showed significant improvement in depression scores with no meaningful difference between treatments
Tianeptine was as effective and as safe as paroxetine for ambulatory major depression at the therapeutic dose
Both drugs were effective and well tolerated in the treatment of major depression, with 75% of tianeptine-treated and 67% of fluoxetine-treated patients meeting responder criteria.
Novotny V, Faltus F. · Human Psychopharmacology (2002)
6-week randomized, double-blind multicentre trial in 178 patients with major depression: tianeptine 37.5 mg/day versus fluoxetine 20 mg/day
Comparable responder rates (75% tianeptine vs 67% fluoxetine) with good tolerability for both
Reinforces the meta-analysis with an independent head-to-head RCT showing tianeptine matches an SSRI at the therapeutic dose
Tianeptine is an efficacious mu-opioid receptor (MOR) agonist ... activation of MOR (or dual activation of MOR and DOR) could be the initial molecular event responsible for triggering many of the known acute and chronic effects of this agent, including its antidepressant and anxiolytic actions.
Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D. · Translational Psychiatry (2014)
Radioligand-binding and cell-based functional assays establishing tianeptine as a full mu-opioid receptor (MOR) agonist (Ki ~383 nM; EC50 ~194 nM for G-protein activation) and a lower-potency delta-opioid agonist, inactive at the kappa receptor
Identifies mu-opioid agonism as the likely molecular trigger for tianeptine's antidepressant and anxiolytic effects
Mechanistic basis for BOTH its therapeutic action AND its abuse/dependence/withdrawal liability — the single most important pharmacology finding for harm reduction
Tianeptine exposure calls, including those for intentional abuse or misuse, increased across the United States during 2014-2017, suggesting a possible emerging public health risk ... a substantial number of tianeptine exposure calls also reported clinical effects of withdrawal.
El Zahran T, Schier J, Glidden E, Kieszak S, Law R, Bottei E, Aaron C, King A, Chang A. · MMWR. Morbidity and Mortality Weekly Report (2018)
National Poison Data System surveillance of all US tianeptine exposure calls, 2000-2017 — a population-level signal of misuse and harm
Exposures rose sharply over 2014-2017, mostly in adults aged 21-40, with neurologic, cardiovascular and gastrointestinal effects, some mimicking opioid toxicity; a substantial number reported withdrawal
Common coexposures were phenibut, ethanol, benzodiazepines and opioids — the dangerous-combination signal
Tianeptine is a drug with potential for abuse and addiction ... caution is advised when prescribing tianeptine to patients with a history of substance abuse, with close monitoring during treatment.
Springer J, Cubała WJ. · Journal of Psychoactive Drugs (2018)
Structured review of 18 published case reports of tianeptine abuse and dependence in psychiatric patients
Documents a clear pattern of abuse and addiction with dose escalation to many times the therapeutic dose and opioid-like withdrawal, concentrated in patients with prior substance-use disorder
Concludes tianeptine has genuine abuse/addiction potential and warrants caution and monitoring when prescribed